Literature DB >> 31478942

Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis.

Masayuki Saijo1, Keiichiro Nakamura1, Naoyuki Ida1, Atsuko Nasu2, Tadashi Yoshino3, Hisashi Masuyama1, Hiroyuki Yanai2.   

Abstract

Endometrial carcinosarcoma (ECS) is a rare and aggressive mixed-type epithelial and mesenchymal tumor. This study focused on the histologic appearance, loss of DNA mismatch repair (MMR) protein expression, and aberrant p53 expression in the epithelial component, and overall prognosis of 57 cases with ECS. Histologically, 21 and 36 cases exhibited low-grade (endometrioid grade 1 and 2) and high-grade (others) epithelial components, respectively. In a Kaplan-Meier analysis, patients with a high-grade epithelial component exhibited worse progression-free survival (PFS), compared with those with a low-grade component. Although the former group also exhibited worse overall survival, the difference was not significant. Thirty-six cases exhibited aberrant p53 expression. Of these, 5 cases exhibited focally aberrant p53 expression in carcinomatous components with diffuse aberrant p53 expression in mesenchymal components. Aberrant expression of p53 did not show significant association with prognosis. Six patients with MMR deficiency exhibited relatively better PFS. In conclusion, a low-grade epithelial component is a superior predictor of the PFS of ECS, compared with MMR protein and p53 expression status. In some cases of ECS, TP53 mutation may be a late event associated with histogenesis of the sarcomatous component.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31478942     DOI: 10.1097/PAS.0000000000001353

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

Review 1.  Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.

Authors:  Antonio Travaglino; Antonio Raffone; Diego Raimondo; Damiano Arciuolo; Giuseppe Angelico; Michele Valente; Giulia Scaglione; Nicoletta D'alessandris; Paolo Casadio; Frediano Inzani; Antonio Mollo; Angela Santoro; Renato Seracchioli; Gian Franco Zannoni
Journal:  Int J Gynaecol Obstet       Date:  2021-10-11       Impact factor: 4.447

2.  Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.

Authors:  Ileana C Cuevas; Subhransu S Sahoo; Ashwani Kumar; He Zhang; Jill Westcott; Mitzi Aguilar; Jeremy D Cortez; Stephanie A Sullivan; Chao Xing; D Neil Hayes; Rolf A Brekken; Victoria L Bae-Jump; Diego H Castrillon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-26       Impact factor: 11.205

3.  Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.

Authors:  Yusuke Kobayashi; Ikumi Kitazono; Toshiaki Akahane; Shintaro Yanazume; Masaki Kamio; Shinichi Togami; Sachio Nohara; Ippei Sakamoto; Seiya Yokoyama; Kazuhiro Tabata; Hiroaki Kobayashi; Akihide Tanimoto
Journal:  Pathol Oncol Res       Date:  2021-12-23       Impact factor: 3.201

Review 4.  The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review.

Authors:  Amelia Favier; Justine Varinot; Catherine Uzan; Alex Duval; Isabelle Brocheriou; Geoffroy Canlorbe
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

5.  Immunohistochemical evaluation of mismatch repair proteins and p53 expression in extrauterine carcinosarcoma/sarcomatoid carcinoma.

Authors:  Michał Kunc; Anna Gabrych; Bartłomiej Rękawiecki; Adam Gorczyński; Johannes Haybaeck; Wojciech Biernat; Piotr Czapiewski
Journal:  Contemp Oncol (Pozn)       Date:  2020-03-30

6.  Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network.

Authors:  Clémence Romeo; Olivia Le Saux; Margaux Jacobs; Florence Joly; Gwenael Ferron; Laure Favier; Jean-David Fumet; Nicolas Isambert; Pierre-Emmanuel Colombo; Renaud Sabatier; Ludovic Bastide; Amandine Charreton; Mojgan Devouassoux-Shisheboran; Witold Gertych; Coraline Dubot; Diana Bello Roufai; Guillaume Bataillon; Dominique Berton; Elsa Kalbacher; Patricia Pautier; Christophe Pomel; Caroline Cornou; Isabelle Treilleux; Audrey Lardy-Cleaud; Isabelle Ray-Coquard
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.